Neurocognitive effects of brivaracetam, levetiracetam, and lorazepam.

摘要: Purpose Brivaracetam (BRV) is a new anticonvulsant under development. Although BRV an analog of levetiracetam (LEV), in addition to being SV2A ligand, it also inhibits sodium channels voltage-dependent manner. The cognitive effects are uncertain. Methods A randomized, double-blind, placebo-controlled, four-way cross-over design was employed 16 healthy volunteers comparing acute dosing (i.e., two doses) 10 mg, LEV 500 lorazepam (LZP) 2 and placebo. primary outcome the summary score from neurophysiologic test (CNT), which combines electrophysiologic performance measures. Secondary outcomes included CNT subscores, traditional neuropsychological measures, treatment-emergent adverse events (TEAEs). Results Compared BRV, LEV, placebo, LZP adversely affected majority subscores In contrast, did not differ placebo or on any measure. More TEAEs occurred with compared each other treatment conditions. Discussion differential pattern drug consistent across multiple electrophysiologic, cognitive, subjective profile subjective, for similar compound findings suggest that should be tolerated well perspective, but additional studies needed.